What is Brainsgate?
Established in 2000, BrainsGate operates at the intersection of medical technology and neuroscience. The company specializes in developing innovative therapies designed to mitigate the long-term disability associated with ischemic stroke and other CNS-related conditions. Its core platform technology utilizes targeted electrical stimulation to enhance cerebral blood flow, offering a novel mechanism of action that distinguishes it from traditional pharmacological interventions. As a player in the medical device space, BrainsGate maintains a robust intellectual property portfolio and a clear focus on improving patient outcomes through precision-engineered hardware solutions.
How much funding has Brainsgate raised?
Brainsgate has raised a total of $40M across 2 funding rounds:
Unspecified
$26M
Private Equity
$14M
Unspecified (2015): $26M with participation from Elron Electronic Industries
Private Equity (2020): $14M led by Elron Electronic Industries Ltd., Cipio, Pitango Venture Capital, Medtronic plc, BNP Paribas, Agate Inc, and Spero Health Inc
Key Investors in Brainsgate
Elron Electronic Industries
A foundational Israeli technology holding company with a long history of fostering innovation across sectors including medical technology, software, and semiconductors.
Pitango Venture Capital
A prominent venture capital firm that supports visionary entrepreneurs from stealth mode to maturity, with a dedicated focus on the HealthTech sector.
BNP Paribas
A leading international banking group that provides comprehensive financing, advisory, and capital market solutions to support innovation and large-scale corporate growth.
What's next for Brainsgate?
With the recent capital injection, BrainsGate is poised to transition into a more mature phase of its corporate lifecycle, focusing on large-scale clinical validation and potential commercialization pathways. The strategic backing from diverse financial institutions suggests a multi-pronged approach to market entry, likely involving rigorous regulatory milestones and the expansion of its clinical trial infrastructure. As the company continues to refine its SPG stimulation technology, the focus will shift toward establishing standard-of-care protocols for stroke management, thereby solidifying its position as a leader in the neuro-therapeutic landscape.
See full Brainsgate company page
